Paul Herzich - 02 Dec 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Chief Technology Officer
Signature: /s/ David Tyronne Howton as attorney-in-fact for Paul Herzich
Issuer symbol: SLDB
Transactions as of: 02 Dec 2024
Net transactions value: -$15,551
Form type: 4
Filing time: 04 Dec 2024, 16:42:47 UTC
Previous filing: 16 Feb 2024
Next filing: 11 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Options Exercise		+7,239	+94%		14,959	02 Dec 2024	Direct	F1, F2
transaction	SLDB	Common Stock	Sale	$15,551	-2,777	-19%	$5.60	12,182	03 Dec 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Restricted Stock Units	Options Exercise	$0	-7,239	-33%	$0.000000	14,478	02 Dec 2024	Common Stock	7,239		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2	Includes 1,698 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024.
F3	This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Dr. Herzich.
F4	The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.